Your browser doesn't support javascript.
loading
Outcome of childhood acute lymphoblastic leukemia treatment in a single center in Brazil: A survival analysis study.
Bonilha, Thais A; Obadia, Danielle D A; Valveson, Andressa C; Land, Marcelo G P.
Afiliação
  • Bonilha TA; Department of Pediatrics, Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti - Hemorio, Rio de Janeiro, Brazil.
  • Obadia DDA; Clinical Medicine Post-Graduation Program, College of Medicine, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
  • Valveson AC; Department of Pediatrics, Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti - Hemorio, Rio de Janeiro, Brazil.
  • Land MGP; Department of Pediatrics, Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti - Hemorio, Rio de Janeiro, Brazil.
Cancer Rep (Hoboken) ; 5(1): e1452, 2022 01.
Article em En | MEDLINE | ID: mdl-34114751
ABSTRACT

BACKGROUND:

Acute lymphoblastic leukemia (ALL) is the most common neoplasm in childhood. The probability of current overall survival (OS) is around 90% in developed countries. There are few studies that demonstrate the results in Brazil.

AIM:

This work aims to analyze the results of children with ALL treated at a single institution in Rio de Janeiro. METHODS AND

RESULTS:

Retrospective analysis survival study of a cohort of childhood ALL patients treated in Hemorio. Kaplan-Meier and log-rank methods were used for the analysis of OS and events-free survival (EFS) and the Cox proportional hazards regression model for multivariate analysis. The probability of OS and EFS at 6 years was 52% and 45%. The probability of OS and EFS in 6 years for patients aged 10-17 years was 31% and 28% and for the younger was 65% and 55%, respectively (p < .001). A probability of OS and EFS in 6 years for patients with more than 100 000 leukocytes/mm3 at diagnosis was 19% and 16% and those with less than 100 000 were 62% (p = .007) and 55% (p = .008). Those who received less than 10 doses of native Escherichia coli asparaginase had a probability of OS and EFS in 6 years of 27% and 21% and those who received at least 10 doses were 74% and 65% (p < .001).

CONCLUSIONS:

The presence of a high number of adolescents and high-risk patients, as well as many patients who discontinued the use of asparaginase or any substitute led to a lower probability of OS and EFS in our cohort.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia-Linfoma Linfoblástico de Células Precursoras Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia-Linfoma Linfoblástico de Células Precursoras Idioma: En Ano de publicação: 2022 Tipo de documento: Article